Bausch + Lomb Posts Record Q4 with 23.5% EBITDA Margin, Eyes 2028 Lens Launch
Q4 revenue reached a company record with EBITDA margin hitting 23.5%, its highest in 172 years. Bausch + Lomb seeks to boost share with its Project Halo bioactive contact lens slated for 2028 launch and grew contact lens revenue 7% plus pharma sales 14% thanks to Mybo.
1. Record Q4 Performance
Bausch + Lomb achieved its highest ever quarterly revenue in Q4, driving a 23.5% EBITDA margin and record EBITDA. This performance builds on a three-year strategic plan focused on disciplined cost management and improved profitability.
2. Project Halo Lens Innovation
The company’s Project Halo represents the first contact lens material innovation since 1999, using a bioactive compound. Topline results from the initial external clinical study show promising outcomes, positioning the lens for a 2028 market launch aimed at capturing additional market share.
3. Pharma Division Expansion
Pharmaceutical sales grew by 14% year-over-year, largely driven by Mybo prescription dry eye treatment in the US. The pharma unit now accounts for a larger share of overall revenue, complementing strong performance in the core contact lens segment.